Brain tumours: Non-invasive techniques to treat invasive pathologies.

Publisher: Elsevier Masson Editeur Country of Publication: France NLM ID: 2985176R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 0003-4509 (Print) Linking ISSN: 00034509 NLM ISO Abbreviation: Ann Pharm Fr Subsets: MEDLINE

Publication: Paris : Elsevier Masson Editeur
Original Publication: Paris : Masson et Cie

Brain Neoplasms*/therapy ; Brain Neoplasms*/drug therapy; Humans ; Blood-Brain Barrier

Brain and other central nervous system tumours are cancers of poor prognosis, for which current therapeutic possibilities do not match the expectations regarding a curative objective. If the treatment of central nervous system tumours is so difficult, it is partly due to the blood-brain barrier and the blood-tumour barrier, which need to be crossed to access the tumour. Driven by these insufficient results, more and more techniques and technologies are being explored and are evolving: the progress of surgery and radiotherapy, the growing place of immunotherapies, or the apparition of new non-invasive techniques. The latter are those which interest us here, where promising advances are taking the leap to clinical trials. Nose-to-brain delivery, receptor-mediated transcytosis and micro-bubbles-associated focused ultrasounds are three therapeutic propositions with encouraging results regarding the improvement of drug access to the brain. Even though they might have their share of limits and adverse effects, benefit-risk balance looks promising, and they may appear as new options to treat patients in the future.
(Copyright © 2023 Académie Nationale de Pharmacie. Published by Elsevier Masson SAS. All rights reserved.)

Keywords: Barrière hémato-encéphalique; Blood-brain barrier; Brain tumour; Clinical trials; Essais cliniques; Non-invasive strategies; Stratégies non-invasives; Tumeurs cérébrales

Date Created: 20231022 Date Completed: 20240226 Latest Revision: 20240226

20240226

10.1016/j.pharma.2023.10.004

37866636